AU2006341375B2 - Amylin and amylin agonists for treating psychiatric diseases and disorders - Google Patents
Amylin and amylin agonists for treating psychiatric diseases and disorders Download PDFInfo
- Publication number
- AU2006341375B2 AU2006341375B2 AU2006341375A AU2006341375A AU2006341375B2 AU 2006341375 B2 AU2006341375 B2 AU 2006341375B2 AU 2006341375 A AU2006341375 A AU 2006341375A AU 2006341375 A AU2006341375 A AU 2006341375A AU 2006341375 B2 AU2006341375 B2 AU 2006341375B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- amylin
- xaa
- hamylin
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPCT/US2006/012601 | 2006-03-31 | ||
| PCT/US2006/012601 WO2006105527A2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| PCT/US2006/038919 WO2007114838A1 (en) | 2006-03-31 | 2006-10-04 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2006341375A1 AU2006341375A1 (en) | 2007-10-11 |
| AU2006341375A2 AU2006341375A2 (en) | 2009-09-24 |
| AU2006341375B2 true AU2006341375B2 (en) | 2013-03-21 |
Family
ID=39876652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006341375A Ceased AU2006341375B2 (en) | 2006-03-31 | 2006-10-04 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2010208A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009538824A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080106950A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006341375B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2647568A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008012666A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007114838A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100204107A1 (en) * | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of urodilatin as a therapeutic agent |
| WO2009043469A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of pneumadin as a therapeutic agent |
| JP2011525895A (ja) * | 2008-06-25 | 2011-09-29 | ノボ・ノルデイスク・エー/エス | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド |
| JP2013511287A (ja) | 2009-11-23 | 2013-04-04 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | ポリペプチド・コンジュゲート |
| BR112013007442A2 (pt) | 2010-09-28 | 2019-09-24 | Amylin Pharmaceuticals Llc | polipeptídeos construídos tendo duração de ação realçada |
| MX349054B (es) | 2010-09-28 | 2017-07-07 | Aegerion Pharmaceuticals Inc | Leptinas altamente solubles. |
| WO2012162547A2 (en) | 2011-05-25 | 2012-11-29 | Amylin Pharmaceuticals, Inc. | Long duration dual hormone conjugates |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686411A (en) * | 1991-03-08 | 1997-11-11 | Amylin Pharmaceuticals, Inc. | Amylin agonist peptides and uses therefor |
| US20050197287A1 (en) * | 2004-03-04 | 2005-09-08 | Mack Christine M. | Methods for affecting body composition |
| WO2006105527A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| ES2108122T3 (es) * | 1991-05-24 | 1997-12-16 | Amylin Pharmaceuticals Inc | Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas. |
| EP1750752A2 (en) * | 2003-11-20 | 2007-02-14 | Neuronova AB | Compounds and methods for increasing neurogenesis |
-
2006
- 2006-10-04 WO PCT/US2006/038919 patent/WO2007114838A1/en not_active Ceased
- 2006-10-04 KR KR1020087023804A patent/KR20080106950A/ko not_active Ceased
- 2006-10-04 JP JP2009502755A patent/JP2009538824A/ja active Pending
- 2006-10-04 CA CA002647568A patent/CA2647568A1/en not_active Abandoned
- 2006-10-04 EP EP06816288A patent/EP2010208A1/en not_active Withdrawn
- 2006-10-04 MX MX2008012666A patent/MX2008012666A/es active IP Right Grant
- 2006-10-04 AU AU2006341375A patent/AU2006341375B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686411A (en) * | 1991-03-08 | 1997-11-11 | Amylin Pharmaceuticals, Inc. | Amylin agonist peptides and uses therefor |
| US20050197287A1 (en) * | 2004-03-04 | 2005-09-08 | Mack Christine M. | Methods for affecting body composition |
| WO2006105527A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Non-Patent Citations (2)
| Title |
|---|
| Flood et al (1992) Peptides, 13(3):577-580 * |
| Moreley et al (1995) Canadian Journal of Physiology and Pharmacology, 73:1042-1046 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2647568A1 (en) | 2007-10-11 |
| WO2007114838A1 (en) | 2007-10-11 |
| AU2006341375A1 (en) | 2007-10-11 |
| MX2008012666A (es) | 2008-10-13 |
| EP2010208A1 (en) | 2009-01-07 |
| JP2009538824A (ja) | 2009-11-12 |
| KR20080106950A (ko) | 2008-12-09 |
| AU2006341375A2 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7671023B2 (en) | Amylin agonist for treating depression, anxiety disorder and schizophrenia | |
| US7399744B2 (en) | Methods for affecting body composition | |
| US7910548B2 (en) | Methods for treating obesity | |
| US7485620B2 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| AU2006341375A2 (en) | Amylin and amylin agonists for treating psychiatric diseases and disorders | |
| EP0964695B1 (en) | Methods and compositions for treating pain | |
| EP2120985B1 (en) | FN-38 peptides for use in the treatment of psychotic and anxiety disorders | |
| US20070275877A1 (en) | Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders | |
| US20090181890A1 (en) | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders | |
| CN101208098A (zh) | 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂 | |
| JP2019525931A (ja) | ヒト成長ホルモンアナログによる成人成長ホルモン欠乏症の処置 | |
| WO2025160184A1 (en) | Methods for the prophylaxis and treatment of obesity and related conditions and disorders | |
| CA2674186A1 (en) | Use of somatostatin analogs in cluster headache |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO DELETE DIVISIONAL AU 2006230602 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 AUG 2009 |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ASTRA ZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUT Free format text: FORMER APPLICANT(S): AMYLIN PHARMACEUTICALS, INC. |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ASTRA ZENECA PHARMACEUTICALS LP Free format text: FORMER APPLICANT(S): ASTRA ZENECA PHARMACEUTICALS LP; AMYLIN PHARMACEUTICALS, LLC |
|
| TH | Corrigenda |
Free format text: IN VOL 27 , NO 5 , PAGE(S) 692 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2006 UNDERTHE NAME ASTRA ZENECA PHARMACEUTICALS LP, APPLICATION NO. 2006341375, UNDER INID (71), CORRECT THE NAME TO ASTRAZENECA PHARMACEUTICALS AND AMYLIN PHARMACEUTICALS, LLC |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |